AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 3 - (NewsRx.com & NewsRx.net) --
Virax Holdings Ltd. (VHL) has entered into a collaborative agreement with Dr. Michael Brown of Royal Adelaide Hospital's Cancer Centre to develop leads for an immune-based therapy to treat prostate cancer.
The therapeutic vaccine to be developed under the agreement will use Virax's platform technology, Co-X-Gene in FPV (fowlpox virus) vector. The prostate cancer program represents an additional application for the technology, which is currently being used in phase I/IIa clinical trial testing Co-X-Gene in FPV for the treatment of HIV.
A short list of leads has been selected for the prostate cancer development program and will undergo testing to determine the ultimate candidate to bring into clinical trials. The company will actively seek grants to fund the early stages of the preclinical and clinical testing.
"Virax's expansion into product development for anti-cancer therapies is an additional application of Co-X-Gene and advances the company's business strategy of developing a broad range of immune-based ...
Source: HighBeam Research, Co-X-Gene Technology Will Target Advanced, Hormone-Refractory...